Brief: Immuneering Completes Dose Escalation In Early-Stage Trial For Solid Tumors Treatment

Immuneering

05/06/2023 14:38

June 5 (Reuters) - Immuneering Corp  IMRX.O :
    * IMMUNEERING COMPLETES DOSE ESCALATION IN THE IMM-1-104
PHASE 1
CLINICAL TRIAL FOR RAS-MUTANT, ADVANCED SOLID TUMORS
    * IMMUNEERING CORP - RECOMMENDED PHASE 2 DOSE (RP2D) AND
ADDITIONAL SAFETY DATA EXPECTED IN EARLY 2024
    * IMMUNEERING CORP - PHASE 1B DOSE EXPANSION HAS COMMENCED;
PLAN
TO ENROLL 21 ADDITIONAL PATIENTS AT 240 MG OR 320 MG DAILY
    * IMMUNEERING CORP-NO DOSE LIMITING TOXICITIES OBSERVED WITH
IMM-1-104 UP TO 320 MG ONCE DAILY DURING PHASE 1A DOSE
ESCALATION PORTION OF ONGOING STUDY

Source text for Eikon:  ID:nGNXblTZR1 
Further company coverage:  IMRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))